Novartis’ Kisqali shows PFS benefit in premenopausal breast cancer
Novartis has unveiled Phase III data showing that partnering Kisqali with an endocrine therapy significantly prolonged progression-free survival compared to an endocrine therapy alone in patients with breast cancer.
Read More
